Achieve Life Sciences Hits Stride with Landmark NDA Submission and FDA Priority Voucher
Achieve Life Sciences is making headlines in the medical community with its latest achievements. The company has recently submitted a new drug application (NDA) for cytisinicline, a novel treatment for nicotine dependence, which marks a significant milestone in the development of this life-changing medication.
According to Rick Stewart, President and Chief Executive Officer of Achieve Life Sciences, the NDA submission is a major step forward in the company's transformation from a pure-play clinical development company into a commercially focused enterprise. This achievement has been made possible by the hard work and dedication of the entire Achieve team, who have demonstrated impressive commitment to addressing the nicotine dependence public health crisis in the U.S.
One of the most notable highlights of 2025 is the FDA's acceptance of the NDA for the smoking cessation indication. This achievement has moved Achieve one important step closer to becoming the first new FDA-approved treatment in 20 years, making cytisinicline a game-changer in the field of nicotine dependence treatment.
Additionally, Achieve's vaping cessation indication was among the first recipients of a Commissioner's National Priority Voucher. This prestigious recognition underscores the significance of cytisinicline in tackling the previously intractable problem of nicotine dependence and provides an accelerated pathway for Achieve to be the first and only FDA-approved vaping cessation treatment.
The company's clinical team has also delivered on all planned regulatory milestones, generating encouraging clinical data across its program during the year. Notably, the ORCA-OL long-term exposure trial demonstrated a strong tolerability profile and excellent patient satisfaction data for cytisinicline, highlighting its safety and efficacy in treating nicotine dependence.
A recent post-hoc analysis published in Thorax, a leading peer-reviewed medical journal, has also shown that cytisinicline significantly improved smoking quit rates compared to placebo in adults with chronic obstructive pulmonary disease (COPD). This breakthrough finding opens up new opportunities for cytisinicline in treating this underserved population and underscores its potential to address various comorbidities associated with nicotine dependence.
Achieve Life Sciences is now poised to capitalize on these achievements, with its commercial team moving forward decisively towards building a scalable, data-driven commercial model that will position the company for successful launches of cytisinicline. As Rick Stewart emphasized, the need for a new nicotine dependence treatment like cytisinicline has never been greater, and Achieve is committed to providing this innovative therapeutic tool to patients seeking to break free from the cycle of nicotine dependence.
The future looks bright for Achieve Life Sciences as it takes significant strides towards bringing this groundbreaking medication to market. With its robust pipeline and commitment to addressing a major public health crisis, the company is well-positioned for continued growth and success in the medical community.
